Syndax Pharmaceuticals Inc (NASDAQ: SNDX) is -0.76% lower on its value in year-to-date trading and has touched a low of $12.06 and a high of $25.07 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The SNDX stock was last observed hovering at around $12.61 in the last trading session, with the day’s gains setting it 0.51%.
Currently trading at $13.12, the stock is -8.02% and -7.69% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.25 million and changing 4.04% at the moment leaves the stock -26.10% off its SMA200. SNDX registered -44.22% loss for a year compared to 6-month loss of -27.91%. The firm has a 50-day simple moving average (SMA 50) of $14.2136 and a 200-day simple moving average (SMA200) of $17.753075.
The stock witnessed a -10.26% gain in the last 1 month and extending the period to 3 months gives it a -5.81%, and is 0.00% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.27% over the week and 6.08% over the month.
Syndax Pharmaceuticals Inc (SNDX) has around 270 employees, a market worth around $1.13B and $23.68M in sales. Profit margin for the company is -1346.11%. Distance from 52-week low is 8.79% and -47.67% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.31%).
with sales reaching $15.43M over the same period.The EPS is expected to shrink by -3.14% this year, but quarterly earnings will post 277.26% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
293.0 institutions hold shares in Syndax Pharmaceuticals Inc (SNDX), with institutional investors hold 117.82% of the company’s shares. The shares outstanding are 85.69M, and float is at 84.15M with Short Float at 22.82%. Institutions hold 116.29% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.91 million shares valued at $$162.33 million. The investor’s holdings represent 9.2788 of the SNDX Shares outstanding. As of 2024-06-30, the second largest holder is WELLINGTON MANAGEMENT GROUP LLP with 7.34 million shares valued at $$150.67 million to account for 8.6063 of the shares outstanding. The other top investors are KYNAM CAPITAL MANAGEMENT, LP which holds 5.72 million shares representing 6.7101 and valued at over $$117.47 million, while VANGUARD GROUP INC holds 5.6295 of the shares totaling 4.8 million with a market value of $$98.48 million.
Syndax Pharmaceuticals Inc (SNDX) Insider Activity
The most recent transaction is an insider sale by Metzger Michael A, the company’s Chief Executive Officer. SEC filings show that Metzger Michael A sold 7,814 shares of the company’s common stock on Mar 04 ’25 at a price of $15.05 per share for a total of $0.12 million. Following the sale, the insider now owns 0.3 million shares.
Still, SEC filings show that on Feb 10 ’25, Goldan Keith A. (Chief Financial Officer) disposed off 3,777 shares at an average price of $15.50 for $58559.0. The insider now directly holds 90,746 shares of Syndax Pharmaceuticals Inc (SNDX).
